00775

0.4902.00%
KM

Kean Meng Toh

VP, Chief Scientific Officer & Executive Director

Dr. Kean Meng Toh, also known as Melvin, M.D., MBBS, serves as Director of Dogwood Therapeutics, Inc. (formerly known as Virios Therapeutics, Inc.) since October 07, 2024. Dr. Toh has been Vice President, Chief Scientific Officer and Executive Director of CK Life Sciences Int'l., (Holdings) Inc. since November 15, 2018. He served as Vice President of Pharmaceutical Development at CK Life Sciences International Holdings Inc until November 15, 2018. Dr. Toh joined the Group in January 2008. Dr. Toh has over 25 years of experience in clinical medicine and pharmaceutical research and development and has held various management and scientific positions in Asia and the U.S. He served as Vice President of Clinical & Regulatory Affairs at CK Life Sciences International Holdings Inc. Prior to joining the CK Life Sciences in January 2008, Dr. Toh served as Director of Clinical Pharmacology in Oncology Development at Pfizer Global R&D, U.S., where he headed a team of scientists working on the clinical development of new cancer drugs. He served as Head and Medical Director of the Pfizer Clinical Research Unit at the Singapore General Hospital. He has been a Director of Wex Pharmaceuticals Inc. since October 21, 2009. Dr. Toh earned his MBBS medical degree from The National University of Singapore and is registered with the Singapore Medical Council and General Medical Council, U.K. He also holds a Master of Science degree in Epidemiology from the University of London.

Positions